eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2017
vol. 21
 
Share:
Share:
abstract:
Review paper

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide

Beata Kos-Kudła
,
Jarosław Ćwikła
,
Marek Ruchała
,
Alicja Hubalewska-Dydejczyk
,
Barbara Jarzab
,
Jolanta Krajewska
,
Grzegorz Kamiński

Contemp Oncol (Pozn) 2017; 21 (2): 115–122
Online publish date: 2017/06/30
View full text Get citation
 
PlumX metrics:
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a large and very diverse group of neoplasms. Clinical presentation of NETs depends on the site of the primary tumor and whether the tumor is functioning (i.e., secreting peptides or neuroamines that produce symptoms). The diagnosis of GEP-NET is further complicated by symptomatic differences that occur depending on the type of secreted peptide or neuroamine. Due to their heterogeneity and unique characteristics, early diagnosis of GEP-NETs is difficult, which increases the likelihood of metastatic disease and reduces the scope of therapeutic possibilities. Thus, a multidisciplinary approach for the treatment of GEP-NETs is necessary. This review is the result of presentations that were delivered during an expert meeting on the treatment of GEP-NETs supported by Ipsen. We summarize the current knowledge on the epidemiology, incidence, diagnosis, and treatment of GEP-NETs. We examined the role of the somatostatin analog (SSA) lanreotide and the impact of the data from the recently published, randomized, double-blind, placebo-controlled CLARINET study (Controlled study of Lanreotide Antiproliferative Response In Neuroendocrine Tumors) on disease management. We also review the recent treatment options and recommendations for GEP-NETs.
keywords:

gastroenteropancreatic neuroendocrine tumors, GEP-NETs, somatostatin analogue, lanreotide, CLARINET

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.